[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100054190":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":50,"collaborators":26,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":56,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":84,"whyStopped":26,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Shanghai Chest Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Segmentectomy","EXPERIMENTAL","Participants assigned to this arm will undergo anatomic pulmonary segmentectomy. Combined segmentectomy or proper segmentectomy is permitted; basal segmentectomy (S7-10) is prohibited. Segmentectomy must include anatomic treatment of the segmental hilar artery, vein, and bronchus, margin assessment, and required lymph-node dissection. Conversion to lobectomy is permitted or required according to protocol-defined clinical and safety criteria.",[13],"Procedure: Anatomic Segmentectomy",{"label":15,"type":16,"description":17,"interventionNames":18},"Lobectomy","ACTIVE_COMPARATOR","Participants assigned to this arm will undergo standard anatomic pulmonary lobectomy with required systematic or lobe-specific lymph-node dissection.",[19],"Procedure: Anatomic Lobectomy",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Anatomic Segmentectomy","Anatomical resection of the involved pulmonary segment or segments with lymph-node dissection and surgical quality-control assessment.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Anatomic Lobectomy","Anatomical resection of the involved pulmonary lobe with lymph-node dissection.",[15],[32],{"facility":5,"status":26,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Shanghai","Shanghai Municipality","200030","China","CN",{"type":39,"coordinates":40},"Point",[41,42],121.45806,31.22222,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":26,"email":49},"Qing Shanghai Chest Hospital","CONTACT","18516349006","pillawang@163.com",{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Zhigang Li","Professor","100054190","segmentectomy-versus-lobectomy-for-deep-solid-dominant-early-stage-nsclc-100054190",false,"NCT07698990","Segmentectomy Versus Lobectomy for Deep Solid-Dominant Early-Stage NSCLC","Comparison of Segmentectomy and Lobectomy for Deeply Located, Solid-Dominant Early-Stage Non-Small Cell Lung Cancer (\u003C=2 cm): A Multicenter, Open-Label, Phase III, Randomized, Controlled, Non-Inferiority Clinical Trial","SOLID","Inclusion Criteria:\n\n1. Age 18 to 80 years.\n2. Solitary pulmonary nodule with maximum diameter \\\u003C=2 cm confirmed by preoperative thin-slice CT (\\\u003C=1 mm) and 3D reconstruction.\n3. Solid-dominant nodule with consolidation-to-tumor ratio (CTR) \\>0.5, including pure-solid nodules.\n4. Deeply located lesion, defined as the lesion center located in the inner two-thirds of the lung field on axial, coronal, and sagittal MPR images.\n5. Clinically definite suspected primary NSCLC after complete preoperative work-up and MDT discussion, with estimated malignancy probability \\>=95%. Preoperative pathologic confirmation is not mandatory, but preoperative or intraoperative pathology should be obtained when technically safe and feasible.\n6. Complete staging with thin-slice contrast-enhanced chest CT, whole-body PET-CT, brain contrast-enhanced MRI or CT, and serum tumor markers as appropriate; clinical stage IA (cT1a-bN0M0) without regional nodal or distant metastasis.\n7. Cardiopulmonary function sufficient to tolerate both lobectomy and segmentectomy, with FEV1 and DLCO \\>=60% predicted.\n8. Written informed consent, including special disclosure that final pathology may be benign.\n9. Centralized imaging review confirmation by the lead-center technical committee before randomization.\n\nExclusion Criteria:\n\n1. Lesion located in the right middle lobe.\n2. Lesion located in the inner two-thirds but adjacent to the lung apex or base and judged suitable for wedge resection.\n3. Two or more lesions requiring anatomic resection. One secondary lesion requiring only non-anatomic wedge resection is allowed; two main lesions in the same segment are excluded.\n4. Prior ipsilateral lung surgery or another malignancy within 5 years.\n5. Severe cardiovascular or cerebrovascular disease or other comorbidity making lobectomy or conversion to lobectomy intolerable.\n6. Planned basal segmentectomy (S7-10); proper segmentectomy is permitted.","ALL","18 Years","80 Years",{"count":66,"type":67},1200,"ESTIMATED","INTERVENTIONAL",[70],"NA","SOLID is a multicenter, open-label, randomized, controlled, phase III non-inferiority trial comparing anatomic segmentectomy with lobectomy in patients with deeply located, solid-dominant, clinical stage IA non-small cell lung cancer (NSCLC) measuring \\\u003C=2 cm. Eligible participants will undergo centralized imaging review and will be randomized preoperatively in a 1:1 ratio before induction of anesthesia.\n\nThe primary endpoint is 5-year overall survival. The key supportive secondary endpoint is 5-year recurrence-free survival. The study will enroll 1,200 participants and will use intention-to-treat analysis for the primary endpoint. An independent Data and Safety Monitoring Board and an independent Endpoint Adjudication Committee will oversee safety, surgical quality, data quality, and endpoint adjudication.",[73,74],"Non-Small Cell Lung Cancer","Stage IA Non-Small Cell Lung Cancer",[76,77,78,79,80,81,82,83],"segmentectomy","lobectomy","deep pulmonary nodule","solid-dominant nodule","early-stage NSCLC","non-inferiority trial","overall survival","recurrence-free survival","NOT_YET_RECRUITING","2026-07-07",{"date":87,"type":88},"2026-07-13","ACTUAL",{"date":90,"type":67},"2026-07",{"date":92,"type":67},"2034-07",{"name":5,"class":6},1]